SABCS

Radius Health, Inc. (Nasdaq:RDUS) today provided an update on data from the Phase 1 005 clinical study of elacestrant (RAD1901), an oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor positive (ER+) breast cancer. The data were presented at a Spotlight Presentation (Abstract 1410) during the 2017 San Antonio Breast Cancer Symposium (SABCS). Elacestrant recently received Fast Track designation from the U.S. Food and Drug Administration. Read More ›

The combination of abemaciclib plus anastrozole is superior to anastrozole alone in reducing Ki67 across a spectrum of subgroups of patients with hormone receptor (HR)-positive, HER2-negative breast cancer. Read More ›

Abemaciclib, but not ribociclib or palbociclib, exhibits inhibition of CDK4/6 plus kinases other than CDK4/6, and induces cell death rather than cytostasis, which may be therapeutically advantageous in patients with hormone receptor‒positive breast cancer that is generally resistant to CDK4/6 inhibitors. Read More ›

Researchers have identified a CDK4/6 inhibitor–sensitive E2F4 gene expression signature in estrogen receptor (ER)-positive breast cancers resistant to aromatase inhibitors that can potentially identify patients with ER-positive breast cancer who are candidates for adjuvant therapy with CDK4/6 inhibitors in combination with antiestrogens. Read More ›

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib. Read More ›

Hot Topics at SABCS 2017
Dr Hope Rugo provides an overview of some hot topics being covered at SABCS 2017 in the areas of hormone therapy, immunotherapy, neoadjuvant therapy, and more. Read More ›

HER2+ Breast Cancer and CDK4/6 Inhibitors
Dr Hope Rugo discusses studies that are aiming to evaluate the effect that CDK4/6 inhibitors have on patients with HER2+ breast cancer. Read More ›

Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor. Read More ›

What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Dr Hope Rugo addresses some of the main differences between the 3 CDK4/6 inhibitors that are FDA-approved in HR-positive metastatic breast cancer. Read More ›

Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Dr Hope Rugo cites that CDK4/6 inhibitors play a critical role in estrogen signaling and can be very effective in treating metastatic breast cancer when used in combination with hormone therapy. Read More ›

Page 3 of 4


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: